Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > PFUDA 10/3 Date

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Aug 18, 2022 3:04pm

202 Views

Post# 34905479

RE:RE:RE:PFUDA 10/3 Date

just so you are clear, biobob indicated 10/3 was about the pen injector, which is incorrect. It is about the approval of the IV Push form of administration of Trogarzo. The pen injector is being developed for use with Egrifta in NASH and lipodystrophy and it seems to be something of a problem as it has taken a very long time to get done. We have not had an update on it in quite a while.